GLP-1 / GIP bireceptor agonists, GLP-1 / GCG bireceptor agonists, and GLP-1 / GIP / GCG triplereceptor agonists
GLP-1/GIP/GCG triple receptor agonists with tailored amino acid sequences and fatty acid conjugations address the limitations of current T2DM treatments by enhancing weight loss and reducing side effects, providing effective glucose control and long-lasting therapy.
Patent Information
- Application Number
- JP2025571467
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-06-09
- Filing Date
- 2024-06-07
- Publication Date
- 2026-07-24
AI Technical Summary
Current therapies for type 2 diabetes mellitus (T2DM) and related comorbidities such as hyperlipidemia, metabolic syndromes, metabolic dysfunction-related fatty liver disease, neurodegenerative disorders, fibrosis, and obesity lack effective treatments that provide glucose control with weight loss benefits while minimizing adverse effects like increased heart rate and cardiac arrhythmias, and require frequent dosing.
Development of GLP-1/GIP/GCG triple receptor agonists with specific amino acid sequences and fatty acid conjugations that enhance weight loss without reducing food consumption and minimize side effects, offering a long-lasting therapeutic effect.
The GLP-1/GIP/GCG triple receptor agonists provide balanced metabolic benefits, including effective glucose control and weight loss with reduced adverse effects, allowing for less frequent dosing.